Compared to the control or PBS-injected T2DM mice, both MSC-sEV- and Ap-MSC-sEV-treated mice showed enhanced insulin sensitivity, driven by an increase in the p-Akt/Akt ratio (P < 0.05). Here, AKT1 is linked to type 2 diabetes mellitus.